Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1

Status

Recruiting 3Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1NETWORK 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Lymphatic Abnormalities 2Lymphangioma, Cystic 2Lymphangioma 2Breast Neoplasms 2Vascular Malformations 1Triple Negative Breast Neoplasms 1Skin Diseases, Vascular 1Ovarian Neoplasms 1Neoplasm Metastasis 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Arteriovenous Malformations 1

Interventions

Specimen Handling 415Magnetic Resonance Spectroscopy 332pembrolizumab 261Biopsy 227Carboplatin 216Cisplatin 179Cyclophosphamide 174Paclitaxel 148Nivolumab 135Gemcitabine 130Radiotherapy 120Dexamethasone 105Bevacizumab 101fludarabine 95Radiation 94Fluorouracil 93Pemetrexed 88Doxorubicin 88Docetaxel 83Rituximab 82venetoclax 81durvalumab 81Oxaliplatin 81Leucovorin 76atezolizumab 68Lenalidomide 66Capecitabine 66Prednisone 65Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Alpelisib × 30 days × Clear all
NCT05564377 2026-05-27

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05392608 2026-05-22

SEQUEL-Breast

Borstkanker Onderzoek Groep

Phase 2 Active not recruiting
130 enrolled
Breast

Breast Neoplasms, Genetic Diseases, Inborn

NCT05948943 2026-05-12

EPIK-L1

Novartis

Phase 2/3 Recruiting
232 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT04251533 2026-05-11

EPIK-B3

Novartis

Phase 3 Terminated
137 enrolled 21 charts
Breast

Triple Negative Breast Neoplasms

NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

NCT05983159 2026-05-05

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting
50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡